EGFR

Biomarkers

EGFR is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
EGFR Exon 20 (Insertion)	Somatic Variant	5	7
EGFR somatic variants	Somatic Variant	4	7
EGFR p.T790M	Somatic Variant	2	4
EGFR Exon 19 (Deletion)	Somatic Variant	13	23
EGFR p.L858R	Somatic Variant	13	23
Wild type EGFR	Wild type	37	81
EGFR oncogenic variants	Somatic Variant	7	13

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab
FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib
FDA (1)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan
FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib
FDA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Afatinib
EMA (1) FDA (1) HSE (2)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
EMA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
EMA (1) FDA (1) HSE (1)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
FDA (1)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib
EMA (2) FDA (3) HSE (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
EMA (3) FDA (2)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
EMA (1) FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
EMA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
EMA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
EMA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib
EMA (2) FDA (3) HSE (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
EMA (3) FDA (2)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
EMA (1) FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
EMA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
EMA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
EMA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
FDA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
EMA (2) FDA (2) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
EMA (1) FDA (1) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
FDA (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
EMA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
EMA (1) HSE (2)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
EMA (1) HSE (1)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Pembrolizumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Pembrolizumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab
EMA (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
EMA (2) HSE (6)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
EMA (1)	Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) HSE (3)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pemetrexed, Tislelizumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pemetrexed, Tislelizumab
EMA (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
EMA (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Gefitinib
EMA (1) HSE (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Afatinib
EMA (1) HSE (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Osimertinib
EMA (2) HSE (2)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
EMA (1) HSE (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Dacomitinib
HSE (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib